5. Recent articles, selected TauRx presentations and reviews (2005 – 2009)

Deiana S, Harrington CR, Wischik CM, Riedel G. (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology 202:53-65.

View abstract

Luna-Munoz J, Peralta-Ramirez J, Chavez-Macias L, et al. (2008) Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Acta Neuropathologica 116:507-515.

View abstract

Wischik C, Staff R. (2009) Challenges in the conduct of disease-modifying trials in Alzheimer's disease: practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy. J Nutr Health Aging 13:367-369.

View abstract

Wischik CM, Wischik DJ, Storey JMD, Harrington C. (2010) Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In Emerging drugs and targets for Alzheimer's disease. Volume 1: ß-Amyloid, Tau Protein and Glucose Metabolism, ed. A. Martinez. pp. 210-232. RSC Drug Discovery Series Cambridge: Royal Society of Chemistry.

Download